We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.42 | -0.64% | 65.09 | 65.11 | 65.40 | 65.80 | 64.89 | 65.75 | 5,571,501 | 00:55:03 |
From May 2019 to May 2024
By Michael Dabaie
Gilead Sciences Inc. said Wednesday that Michael Quigley joined the company as senior vice president of research biology.
Mr. Quigley joined the biopharmaceutical company from Bristol-Myers Squibb, where most recently he was vice president and head of Tumor Microenvironment Modulation Thematic Research Center and site head of the Redwood City, Calif., location.
The company also said it named Linda Higgins as senior vice president and head of external innovation. Ms. Higgins joined Gilead in 2010, leading a significant expansion of the company's Biology organization that included the establishment of Biologics and Biomarker functions, as well as the addition of inflammation, oncology and immunology discovery groups.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
February 19, 2020 09:07 ET (14:07 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
